Harpoon rises over positive interim data in early-stage blood cancer trial

Harpoon Therapeutics

12/12/2022 11:31

** Shares of drug developer Harpoon Therapeutics Inc
 HARP.O  rise 7.8% at $1.24 before the bell
    ** Co late on Sunday reported updated positive interim data
from early-stage experimental treatment - HPN217 - for
relapsed/recurring blood cancer that affects plasma cells
    ** HPN217 showed continued evidence of clinical activity and
a tolerable safety profile in 62 heavily pre-treated patients -
HARP
    ** Co adds it will continue dose optimisation with ongoing
patient enrollment in the trial expected to reach completion in
the first half of 2023
    ** YTD HARP down 84.8%, as of last close 
 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))